More comprehensive evidence on the determinants of funding for early-stage companies, and on what stage companies struggle to secure funding the most.

Background

The analysis team is responsible for two datasets on life sciences activity in the UK and how it compares with other countries. One of its publications, the Bioscience and health technology sector statistics, is an official statistic and captures a detailed breakdown of where life sciences activity occurs in the UK, as well as key economic indicators such as employment and turnover. The analysis team is also responsible for publishing the Life sciences competitiveness indicators, a publication which tracks UK performance against international comparators. These two publications form the bulk of the evidence base that supports OLS policy making and key facts and figures for stakeholders. One of the ambitions of the team is to expand the range of data collected on activity in the sector to encompass a broader range of economic indicators, including Gross Value Added, R&D spending, Wages, and workforce statistics, among others.

In addition to this critical evidence base, OLS is also interested in key research questions and evidence to support the development of policy for the Life Sciences Missions, a set of disease and intervention areas identified in the Life Sciences Vision as key areas of intervention to help the NHS to solve some of the biggest healthcare problems of our generation. These range from establishing a strong evidence base on incidence and its regional distribution to identifying potential innovative technologies that could address them. Additionally, the analysis team is also very interested in deepening our understanding of the economic impact and possibilities of the broad area of genomics, as well as understanding the economic impacts and societal benefits that accrue from conducting clinical trials and other forms of R&D in the life sciences.

On the regulatory front, OLS would like to expand its understanding of the main regulatory barriers to the approval and roll-out of new, innovative technologies, as well as understanding the costs and benefits associated with these regulations. We have a limited evidence base for some products but would like to expand that understanding to be better able to assess the impact of specific regulatory interventions. We would also like to have more comprehensive data on the introduction and adoption of these technologies across the country and through the NHS.

On the investment front, we are particularly interested in building a more comprehensive evidence base on the determinants of investment in both manufacturing and R&D facilities, and how elements of both the commercial and business environment affects company location and investment decisions.

Finally, we are very interested in developing a more comprehensive understanding of the manufacturing landscape in the UK, from being able to interrogate the pipeline of new products and innovations in development, to establishing the UK’s manufacturing capabilities for health and supply chain resilience, as well as understanding key challenges faced by companies in terms of access to skilled workers and finance across the country.

Next steps

If you are keen to register your interest in working and connecting with DSIT Digital Technology and Telecoms Group and/or submitting evidence, then please complete the DSIT-ARI Evidence survey - https://dsit.qualtrics.com/jfe/form/SV_cDfmK2OukVAnirs.
Please view full details: https://www.gov.uk/government/publications/department-for-science-innovation-and-technology-areas-of-research-interest/dsit-areas-of-research-interest-2024

Related UKRI funded projects


  • Better measurement of the complementarity between UK public, charity and private medical research

    Getting benefits from medical research in terms of preventing or treating illness, advancing scientific knowledge and generating economic wealth often, though not always, involves private industry. The private sector bui...

    Funded by: MRC

    Lead research organisation: King's College London

    Why might this be relevant?

    Partially relevant as it focuses on the complementarity between public/charity funded research and private sector R&D, but does not directly address funding determinants for early-stage companies.

  • Experomental Medicine Network of Excellence

    The UK Science base is recognised as internationally excellent and the translation of this excellence into improvements in clinical practice is essential to ensure the continued delivery of UK economic and health benefit...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF BIRMINGHAM

    Why might this be relevant?

    Partially relevant as it addresses factors limiting the translation of scientific excellence into clinical practice, but does not directly focus on funding determinants for early-stage companies.

  • British Regen Industry Tool Set (BRITS)

    The British Regen Industry Tool Set (BRITS) is an industry driven project aimed at establishing reliable market data and creating both detailed bioprocess economics models and higher level business models for integration...

    Funded by: Innovate UK

    Lead research organisation: LONZA BIOLOGICS PLC

    Why might this be relevant?

    Not relevant as it focuses on establishing market data and business models for the cell therapy industry, not related to funding determinants for early-stage companies.

  • West Midlands HealthTech/MedTech ‘6D’ Innovation Accelerator

    The Healthcare Technology and Medical Technology sectors are currently worth £17billion per annum to the UK, and with the ageing population and poor health following the pandemic, are projected to grow to £21...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF BIRMINGHAM

  • Investigation of the impact of co-location: economies of scope and scale in biomedical and health research

    It is important to achieve the best outcomes from public sector investments in medical research. To do this, research funders need to understand where they should invest the limited funds they have available to maximise ...

    Funded by: MRC

    Lead research organisation: RAND Europe

  • Regenerative medicine value systems: navigating the uncertainties

    Delivery of tools to navigate the regen med uncertainties. VALUE has delivered tools for developers, manufactures and funders to understand regulatory requirements, supply chain logistics and reimbursement decision proce...

    Funded by: Innovate UK

    Lead research organisation: BIOLATRIS LIMITED

  • Research and Training to create assets in the form of new companies to develop a new model to generate innovative therapies

    Cancer Research UK has partnered with Deep Science Ventures to create an opportunity for early career stage researchers to build ventures that target the complexity of biology. This partnership brings together the world'...

    Funded by: FLF

    Lead research organisation: Institute of Cancer Research

  • Reliable and Efficient Estimation of the Economic Value of medical Research (REEEVR)

    In the UK, taxpayers and charities pay for most healthcare research. National bodies like the National Institute for Health Research (NIHR) allocate public funds. Charities like Cancer Research UK (CRUK) rely on donation...

    Funded by: MRC

    Lead research organisation: University of Bristol

  • An innovative all-in-one, cost-effective solution to enhancing the connection between innovators and investors in the Life Sciences and Healthcare Sectors.

    Founded by David D'Alton and Rupert Lewis, Oyster Venture Partners Ltd is a rapidly growing British SME in the life sciences and healthcare sector. It aims to achieve near-total automation of the previously cumbersome an...

    Funded by: Innovate UK

    Lead research organisation: OYSTER VENTURE PARTNERS LIMITED

  • Clinical Research Infrastructure and Trials Platform

    The opportunity is to enable the Clinical Trials Units at UoW and UoB to increase the region's market share in clinical trials. The UK Science base is recognised as internationally excellent and the ; j translation of th...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF WARWICK

Similar ARIs from other organisations